5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Xie, Zhao Hui ^a,b   Quan, Mei Fang ^b   Liu, Fei ^b   Cao, Jian Guo ^b   Zhang, Jian Song ^b  

^a Changsha Health Vocational College   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

5 allyl 7 gen difluoromethoxychrysin; Apoptosis; Chrysin; Lung cancer; Therapeutic action; TRAIL

Indexed keywords

5 ALLYL 7 GEN DIFLUOROMETHOXYCHRYSIN; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PROPIDIUM IODIDE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 5 ALLYL 7 GEN DIFLUOROMETHYLENECHRYSIN; 5-ALLYL-7-GEN-DIFLUOROMETHYLENECHRYSIN; BLOCKING ANTIBODY; CASPASE; CHRYSIN; CYSTEINE PROTEINASE INHIBITOR; FLAVONOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIBODIES, BLOCKING; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79960851190     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-322     Document Type: Article

References (49)

1. Densmore CL. Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 2006, 3:55-63. 10.2174/156720106775197547, 16472094.
2. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA 2006, 103:11567-11572. 10.1073/pnas.0603363103, 1518800, 16864783.
3. Hong TB, Rahumatullah A, Yogarajah T, Ahmad M, Yin KB. Potential effects of chrysin on MDA-MB-231 cells. Int J Mol Sci 2010, 11:1057-1069. 10.3390/ijms11031057, 2869226, 20479999.
4. Khoo BY, Chua SL, Balaram P. Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci 2010, 11:2188-2199. 10.3390/ijms11052188, 2885101, 20559509.
5. Woo KJ, Jeong YJ, Park JW, Kwon TK. Chrysin-induced apoptosis is mediated through caspase activation and Akt inactivation in U937 leukemia cells. Biochem Biophys Res Commun 2004, 325:1215-1222. 10.1016/j.bbrc.2004.09.225, 15555556.
6. Zheng X, Cao JG, Liao DF, Liu HT. Systhesis and Anticancer Effect of gem-Difluoromethylenated Chrysin Derivatives. Chinese Chemical Letter 2006, 17:1439-1442.
7. Zheng X, Meng WD, Xu YY, Cao JG, Qing FL. Synthesis and anticancer effect of chrysin derivatives. Bioorg Med Chem Lett 2003, 13:881-884. 10.1016/S0960-894X(02)01081-8, 12617913.
8. Ai XH, Zheng X, Tang XQ, Sun L, Zhang YQ, Qin Y, Liu HQ, Xia H, Cao JG. Induction of apoptosis of human gastric carcinoma SGC-7901 cell line by 5, 7-dihydroxy-8-nitrochrysin in vitro. World J Gastroenterol 2007, 13:3824-3828.
9. Yang XH, Zheng X, Cao JG, Xiang HL, Liu F, Lv Y. 8-Bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J Gastroenterol 2010, 16:3385-3393. 10.3748/wjg.v16.i27.3385, 2904884, 20632440.
10. Li JL, Xie WY, Cao JG. The Effect of 5-allyl-7-gendifluoromethylenechrysin on proliferation and apoptosis in ovarian cancer Cell Cultured in Vitro. Am J Chin Clin Med 2005, 7:323-326.
11. Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. World J Gastroenterol 2009, 15:2234-2239. 10.3748/wjg.15.2234, 2682238, 19437563.
12. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998, 28:973-982. 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T, 9541592.
13. Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000, 275:20632-20637. 10.1074/jbc.M909721199, 10748154.
14. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004, 52:821-831. 10.1369/jhc.3A6112.2004, 15150291.
15. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
16. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997, 272:25417-25420. 10.1074/jbc.272.41.25417, 9325248.
17. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
18. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743. 10.1038/sj.onc.1203489, 10777207.
19. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348. 10.1016/S1359-6101(03)00029-7, 12787570.
20. Walczak H, Haas TL. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol Biol 2008, 414:221-239. 10.1007/978-1-59745-339-4_16, 18175822.
21. Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T. TRAIL-induced apoptosis: between tumor therapy and immunopathology. Ann N Y Acad Sci 2009, 1171:50-58. 10.1111/j.1749-6632.2009.04905.x, 19723037.
22. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12:228-237. 10.1038/sj.cgt.7700792, 15550937.
23. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008, 11:17-24. 10.1016/j.drup.2008.02.001, 2435079, 18374623.
24. Szliszka E BJ MA, Miszkiewicz J, Krol W. Enhanced sensitivity of hormone-refractory prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated cytotoxicity by taxanes. CEJ Urol 2009, 62:29-34.
25. Szliszka E, Czuba ZP, Bronikowska J, Mertas A, Paradysz A, Krol W. Ethanolic Extract of Propolis Augments TRAIL-Induced Apoptotic Death in Prostate Cancer Cells. Evid Based Complement Alternat Med 2009,
26. Szliszka E CZ MB, Sedek L, Paradysz A, Krol W. Chalcones enhances TRAIL-induced apoptosis in prostate cancer cells. Int J Mol Sci 2010, 11:1-13.
27. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-6271. 10.1038/sj.onc.1207830, 15208660.
28. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2006, 5:945-951. 10.1158/1535-7163.MCT-05-0431, 16648565.
29. Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res 2007, 67:4973-4980. 10.1158/0008-5472.CAN-06-4044, 17510428.
30. Chen W, Wang X, Zhuang J, Zhang L, Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 2007, 28:2114-2121. 10.1093/carcin/bgm133, 17548900.
31. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992, 7:171-180.
32. Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 2007, 13:1534-1540.
33. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 2007, 6:1006-1012. 10.1158/1535-7163.MCT-06-0491, 17363494.
34. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003, 100:15095-15100. 10.1073/pnas.2435285100, 299914, 14645705.
35. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004, 96:1769-1780. 10.1093/jnci/djh322, 15572759.
36. Monasterio A, Urdaci MC, Pinchuk IV, Lopez-Moratalla N, Martinez-Irujo JJ. Flavonoids induce apoptosis in human leukemia U937 cells through caspase- and caspase-calpain-dependent pathways. Nutr Cancer 2004, 50:90-100. 10.1207/s15327914nc5001_12, 15572302.
37. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000, 2:241-243. 10.1038/35008667, 10783243.
38. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609. 10.1016/S1074-7613(00)80211-3, 10894160.
39. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620. 10.1016/S1074-7613(00)80212-5, 10894161.
40. Walle T, Ta N, Kawamori T, Wen X, Tsuji PA, Walle UK. Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones. Biochem Pharmacol 2007, 73:1288-1296. 10.1016/j.bcp.2006.12.028, 1868573, 17250812.
41. Wen X, Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 2006, 34:1786-1792. 10.1124/dmd.106.011122, 16868069.
42. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24:1199-1208. 10.1093/carcin/bgg082, 12807727.
43. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004, 23:2554-2558. 10.1038/sj.onc.1207351, 14691451.
44. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008, 13(Suppl 1):28-36.
45. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331. 10.1016/S0092-8674(00)81871-1, 9039259.
46. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878.
47. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010, 9:3254-3266. 10.1158/1535-7163.MCT-10-0582, 21041383.
48. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010, 5:e15627. 10.1371/journal.pone.0015627, 3011015, 21209944.
49. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010, 5:e15288. 10.1371/journal.pone.0015288, 3001855, 21179458.